Bristol-Myers Squibb Co. (NYSE:BMY)

ASCO 2013 gives upside potential !

great pipeline & management

I'm buying this tomorrow because of PD-1

Stock with a PE of almost 50 in an on-average overvalued market due for a significant pullback. With a company this size, the increase in revenue would have to be astronomical to justify the price.

Like all the drugs in the pipeline

Product pipeline has it positioned to outperform its peers during the recovery period.

pharma

Sector
Patent expirations

One of the leaders of an annual industry audit that looks at value creation in the biotech space.

http://caps.fool.com/Blogs/a-look-at-established-biotech/774287

Can dividend reinvestment factor into this pick? Love the yield.

This will underperform the S&P 500 because it is too strong.

Strong company, good fundamentals, good dividend. Bet LONG on BMY.

BMY has in late-stage clinical trials an Alzheimer's Drug with great promise. One of the clinical trials failed to achieve the study's "end-point." The second clinical trial did achieve the end-point.

The failure of the first failed trial has more to say about a poor choice of "end-point" than does the safety and future promise of the drug.

BMY is a STRONG long-term BUY!!!

BMY recently had a dip in share price because one of it' drugs did not receive FA approval. Shares dropped 6+% the day it was announced. I had recently bought at 33 and change and happily added to my position when this slide occurred. I would recommend buying at anytime during this consolidation period. It is my belief that Bristol will outperform in the mid/long term due to it's juicy and sustainable dividend, it's smaller market cap. when compared to companies like Merck or Pfizer, it's wonderful return on equity and operating margins which show it has strong profitability and management. Also, its cash of 5.03B could just about pay off it's debt(5.42B) if needed. Shares outstanding aren't too diluted (unlike companies such as Ford-F NYSE). Bristol also has a strong current ratio of 1.63. Shares are also trading below their 50 and 200 day moving averages, making entering a new position even more promising. Finally, BMY has a current assets: liabilities ratio of 15.318B: 7.780B and total A:L of 32.97:17.014B. This gives BMY a good short and long term outlook. The only thing to weary of is that it has an average 1y target estimate of 34.63, however the "professional's thoughts have never really carried an weight in my mind before".

To good investing from good people

industry

has brought into bio-tech with the purchase of some new bio companies that must show promise otherwise why would they buy these companies.

Solid pipeline. Nice dividend

the street

Good entry point here at a strong support level off of the August 2011 and November 2011 lows